Basis: FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/FCF ratio is N/A as of 2026-10-06T14:57:13.252Z.
Calculation as of: 2026-10-06T14:57:13.252Z.
Quote observation: 2026-10-06T14:54:03.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: cc1b6a3b00dabe5b261e15a58cf0fecaa0dcd4715ed4b38f5f86d2c12a5f1f47
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/FCF RATIO
N/A
Cellyan Biotechnology Co., Ltd
Market Cap
$1.11M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.04M
Price/FCF Ratio
N/A
TTM Avg
60791.74
3Y Avg
60791.74
5Y Avg
60791.74
Market Cap
$1.18M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$870069.00
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$835190.00
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PRICE/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Cellyan Biotechnology Co., Ltd (HKPD) | $1.11M | N/A | N/A | N/A | N/A |
| Clearmind Medicine Inc. (CMND)vs › | $1.08M | N/A | N/A | N/A | N/A |
| Aspire Biopharma Holdings, Inc. (ASBP)vs › | $1.04M | N/A | 60791.74 | 60791.74 | 60791.74 |
| Jupiter Neurosciences, Inc. (JUNS)vs › | $1.18M | N/A | N/A | N/A | N/A |
| IM Cannabis Corp. (IMCC)vs › | $1.19M | N/A | 3.00 | 2.75 | 2.75 |
| Bone Biologics Corporation (BBLG)vs › | $870069.00 | N/A | N/A | N/A | N/A |
| Genprex, Inc. (GNPX)vs › | $1.34M | N/A | N/A | N/A | N/A |
| GlucoTrack, Inc. (GCTK)vs › | $865985.00 | N/A | N/A | N/A | N/A |
| Decoy Therapeutics Inc. (DCOY)vs › | $835190.00 | N/A | N/A | N/A | N/A |
| Artelo Biosciences, Inc. (ARTL)vs › | $1.38M | N/A | N/A | N/A | N/A |
P/FCF Ratio
N/A
FCF Yield
N/A
P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
